BioSpace News Archive

Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and advanced technology mega campuses in AAA innovation cluster locations, today announced an exclusive partnership with longstanding tenant Eli Lilly and Company (NYSE: LLY) to expand Lilly’s innovative Gateway Labs model to the San Diego life science cluster.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that an Extraordinary General Meeting is convened and will take place on Tuesday December 19, 2023, at 11:00 am CET at the Campus Biotech, Chemin des Mines 9, 1202 Geneva.

argenx SE announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo in adults with primary immune thrombocytopenia.

Toyoda Gosei Co., Ltd. has invested* in ThinkCyte K.K., whose technologies are used for a broad spectrum of applications, including the early detection of leukemia and other diseases, with the aim of solving social issues in the healthcare field.

Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, announces initiation of coverage of its stock by analysts at independent financial group ODDO BHF.

Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of EP262 in subjects with atopic dermatitis (AD).

AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of David Meininger, PhD, MBA to the newly created position of Chief Business Officer.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced a global licensing and research collaboration with Bristol Myers Squibb (NYSE: BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.

Praxis Precision Medicines, Inc. announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida.

Apollomics Inc. (Nasdaq: APLM) (the “Company”) today announced a poster presentation of clinical results for vebreltinib in the treatment of NSCLC with MET exon 14 skipping mutation with or without concurrent MET amplification at the 2023 IASLC North America Conference on Lung Cancer (NACLC), being held on December 1 through 3, 2023 in Chicago, Illinois.